Volume 134, Issue 3, Pages 688-695 (March 2008) Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial  James D. Lewis, Gary R. Lichtenstein, Julius J. Deren, Bruce E. Sands, Stephen B. Hanauer, Jeffrey A. Katz, Bret Lashner, Daniel H. Present, Shaokun Chuai, Jonas H. Ellenberg, Lisa Nessel, Gary D. Wu  Gastroenterology  Volume 134, Issue 3, Pages 688-695 (March 2008) DOI: 10.1053/j.gastro.2007.12.012 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Outcome of patients screened and enrolled in the trial. Gastroenterology 2008 134, 688-695DOI: (10.1053/j.gastro.2007.12.012) Copyright © 2008 AGA Institute Terms and Conditions

Figure 2 (A) Proportion of patients achieving the primary and secondary outcomes at week 12. *P = .03; †P = .01. (B) Proportion of patients with improvement in the partial Mayo score (decrease, ≥2 points from baseline). *P = .03; †P = .049; #P = .06. (C) Proportion of patients with improvement in quality of life (Inflammatory Bowel Disease Questionnaire increase, ≥16 points) after 4, 8, and 12 weeks of therapy. ‡P = .04. (D) Proportion of patients with improvement in the individual components of the Mayo score. Improvement was defined as a reduction of at least 1 point. Patients who withdrew from the study before week 12 were categorized as not having improvement. *P = .04; †P = .03; ‡P = .01. (A–C) ■, Rosiglitazone (N = 52); ☐, placebo (N = 53). (D) ■, Rosiglitazone; ☐, placebo. Gastroenterology 2008 134, 688-695DOI: (10.1053/j.gastro.2007.12.012) Copyright © 2008 AGA Institute Terms and Conditions